<DOC>
	<DOCNO>NCT00235794</DOCNO>
	<brief_summary>Open-label exloratory pharmacodynamic pharmacogenomic study evaluate teh biologic effect 3 dose level ( 1mg , 5 mg , 15 mg ) temsirolimus administer orally daily approximately 4 week ( +/- 2 week ) prostatectomy</brief_summary>
	<brief_title>An Open Label Exploratory Study Newly Diagnosed Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm diagnosis adenocarcinoma prostate gland via minimum 6 core biopsy sample . Subjects must candidate radical prostatectomy No evidence metastatic disease determine CT scan bone scan More criterion apply Subjects sufficient diagnostic biopsy material available full characterization tumor Active Infection require antibiotic therapy , serious intercurrent illness , active bleeding , ongoing urinary tract infection necessitate rapid emergent surgical resection Subjects hormonal injection implant last longer 6 month More criterion apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>